News

Tasquinimod works, says Phase II study
Enlarge image

BusinessSwedenFrance

Tasquinimod works, says Phase II study

05.06.2012 - Swedish Active Biotech draws new hope from a Phase II result with prostate cancer drug tasquinimod.

Lund – Almost a year ago Swedish Active Biotech AB saw its stock value dwindling away when the oral multiple sclerosis drug laquinimod failed in crucial Phase III testing. Although the price per share has doubled when compared to the start of the year, SEK44 is still far away from its last 12-month-cycle climax roughly a year ago.

On 4 June, Andrew Armstrong from the Duke Cancer Institute in Durham (USA) presented data on a long-term follow-up of a randomised Phase II placebo-controlled trial with Active Biotech's tasquinimod. The talk, given at the 2012 ASCO Annual Meeting in Chicago (USA), focussed on the median overall survival times of patients suffering from castrate resistant prostate cancer (CRPC) which increased from 30.4 months (placebo) to 33.4 months (tasquinimod). Armstrong expressed that these findings surprised him: "Men with metastatic CRPC in this trial were unexpectedly found to have prolonged survival times, despite a high fraction of patients with liver and lung metastases."  

Active Biotech is developing the drug together with Ipsen group, a pharmaceutical company from Paris (France) employing 4,500 people. Ipsen's CSO Claude Betrand was eager to announce he's pleased with the results: "We are thrilled. The results underline the activity of the compound. With its differentiated mechanism of action [not targeting the androgen receptor pathway] we hope to propose an alternative treatment after the ongoing Phase III results have replicated these interesting findings." So far 600 patients have been recruited for the double-blind Phase III study. In the end the study will include 1,200 patients from more than 250 clinics.

http://www.european-biotechnology-news.com/news/news/2012-02/tasquinimod-works-says-phase-ii-study.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014